Company: HROW
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001641172-25-006102
Chunk: 34

Company: HARROW, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 34
---
 policy discourages placing standing or limit orders on Company securities.

Executive Officers

Executive officers are appointed by our Board and serve at its discretion. Set forth below is information regarding our executive officers as of April 21, 2025.

| Name       |     | Position                                                 |     | Age |
| Mark       
 L. Baum    |     | Chief                                                    
 Executive Officer and Chairman of the Board of Directors |     |  52 |
| Andrew     
 R. Boll    |     | Chief                                                    
 Financial Officer and Corporate Secretary                |     |  42 |
| John       
 P. Saharek |     | President                                                
 and Chief Executive Officer, ImprimisRx                  |     |  65 |
| Amir       
 H. Shojaei |     | Chief                                                    
 Scientific Officer                                       |     |  57 |

Mr. Baum’s biographical information is included with such information for the other members of our Board.

Andrew R. Bollis a founder of Harrow and has worked with the Company since December 2011 and has served as our Chief Financial Officer and Corporate Secretary since his promotion to that role in February 2015. Mr. Boll helped found Eton Pharmaceuticals, Inc., Surface Ophthalmics, Inc., Melt Pharmaceuticals, Inc. and ImprimisRx. Prior to co-founding Harrow, from 2007 to 2011, Mr. Boll worked for an investment company and its series of funds where he oversaw the fund’s accounting, financial analysis, and reporting. He was also closely involved with the financial operations of a number of the fund’s portfolio companies (public and private). Prior to 2007, Mr. Boll held various accounting roles at Welsh Companies, LLC, a commercial real estate company, its fund and its other subsidiaries. Mr. Boll is a CFA ®charterholder, Certified Management Accountant and earned his Bachelor of Science degree, summa cum laude, in Corporate and Public Finance at Huron University.

John P. Saharekhas worked for the Company since 2013 and as ImprimisRx’s President since February 2019, adding the title of Chief Executive Officer of ImprimisRx in 2023. He was previously our Vice-President of Commercialization, Ophthalmology from November 2013 until February 2015, and was then promoted to Chief Commercial Officer. He is a senior healthcare industry executive with over 30 years of broad experience developing and commercializing pharmaceutical, biotechnology,